Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook

References

• Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–1133.
   PubMed Web of Science ®Google Scholar
• Maggioni AP. Epidemiology of heart failure in Europe. Heart Fail Clin. 2015;11:625–635.
   PubMed Web of Science ®Google Scholar
• Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.
   PubMed Web of Science ®Google Scholar
• Van Deursen VM, Damman K, Van Der Meer P, et al. Co-morbidities in heart failure. Heart Fail Rev. 2014;19:163–172.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
   PubMed Web of Science ®Google Scholar
• Borlaug BA. Is HFpEF one disease or many? J Am Coll Cardiol. 2016;67:671–673.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European society of cardiology, the European society of emergency medicine and the society of academic emergency medicine. Eur J Heart Fail. 2015;17:544–558.
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr. Natriuretic peptides as biomarkers in heart failure. J Investig Med. 2013;61:950–955.
   PubMed Web of Science ®Google Scholar
• Bayés-Genís A, Barallat J, Galán A, et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657–665.
   PubMed Web of Science ®Google Scholar
• McMurray JJ. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17:242–247.
   PubMed Web of Science ®Google Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106:920–926.
   PubMed Web of Science ®Google Scholar
• Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004 Feb;17(2):103–111.
   PubMed Web of Science ®Google Scholar
• Gori M, Senni M. Sacubitril/valsartan (LCZ696) for the treatment of heart failure. Expert Rev Cardiovasc Ther. 2016;14:145–153.
   PubMed Web of Science ®Google Scholar
• McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015;36:434–439.
   PubMed Web of Science ®Google Scholar
• Kaplinsky E. PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure? J Geriatr Cardiol. 2015;12:470–473.
   PubMedGoogle Scholar
• Szema AM, Dang S, Li JC. Emerging novel therapies for heart failure. Clin Med Insights Cardiol. 2015;9(Suppl 2):57–64.
   PubMedGoogle Scholar
• Minguet J, Sutton G, Ferrero C, et al. LCZ696: a new paradigm for the treatment of heart failure? Expert Opin Pharmacother. 2015;16:435–446.
   PubMed Web of Science ®Google Scholar
• Mills J, Vardeny O, The role of neprilysin inhibitors in cardiovascular disease. Curr Heart Fail Rep. 2015;12:389–394.
   PubMedGoogle Scholar
• Singh JS, Lang CC. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag. 2015;11:283–295.
   PubMed Web of Science ®Google Scholar
• Gradman AH. LCZ696: the next step in improving RAS inhibition? Curr Hypertens Rep. 2015;17:37.
   PubMed Web of Science ®Google Scholar
• Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029–1041.
   PubMed Web of Science ®Google Scholar
• Miners JS, Kehoe P, Love S. Neprilysin protects against cerebral amyloid angiopathy and Aβ-induced degeneration of cerebrovascular smooth muscle cells. Brain Pathol. 2011;21:594–605.
   PubMed Web of Science ®Google Scholar
• Vodovar N, Paquet C, Mebazaa A, et al. Neprilysin, cardiovascular, and Alzheimer’s diseases: the therapeutic split? Eur Heart J. 2015;36:902–905.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Remuzzi G. Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart? Eur J Heart Fail. 2015;17:468–471.
   PubMed Web of Science ®Google Scholar
• Voors AA, Gori M, Liu LC, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015;17:510–517.
   PubMed Web of Science ®Google Scholar
• Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576–2584.
   PubMed Web of Science ®Google Scholar
• Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990–1997.
   PubMed Web of Science ®Google Scholar
• Simpson J, Jhund PS, Silva Cardoso J, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66:2059–2071.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.
   PubMed Web of Science ®Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.
   PubMed Web of Science ®Google Scholar
• CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet. 2003;362:772–776.
   PubMed Web of Science ®Google Scholar
• Claggett B, Packer M, McMurray JJ, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373:2289–2290.
   PubMed Web of Science ®Google Scholar
• Pellicori P, Clark AL. Clinical trials update from the European society of cardiology-heart failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure. Eur J Heart Fail. 2015;17:979–983.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Felker GM, McMurray JJV, et al. Late-breaking clinical trial abstracts. Circulation. 2015;132:2267–2285. Abstract 24294.
   PubMed Web of Science ®Google Scholar
• Margulies KB, Anstrom KJ, Redfield MM, et al. A randomized trial of liraglutide for high-risk heart failure patients with reduced ejection fraction (FIGHT). American Heart Association 2015 Scientific Sessions; 2015 Nov 8; Orlando, FL. Abstract 20102.
   Google Scholar
• Bundgaard H, Axelsson A, Iversen K, et al. The-first-in-man randomized trial of a β3-adrenoceptor agonist in chronic heart failure - the BEAT-HF trial. Presented at: American Heart Association Scientific Sessions; 2015 Nov 7–11; Orlando, FL. Late-Breaking Clinical Trials 4.
   Google Scholar
• Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314:2251–2262.
   PubMed Web of Science ®Google Scholar
• Böhm M, Robertson M, Ford I, et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT trial). Am J Cardiol. 2015;116:1890–1897.
   PubMed Web of Science ®Google Scholar
• Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17:1050–1056.
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Borghi C. Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin. 2015;31(Suppl. 2):15–19.
   PubMedGoogle Scholar
• Borghi C. The role of uric acid in the development of cardiovascular disease. Curr Med Res Opin. 2015;31(Suppl. 2):1–2.
   PubMedGoogle Scholar
• Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131:1763–1771.
   PubMed Web of Science ®Google Scholar
• Ormerod JO, Arif S, Mukadam M, et al. Short-term intravenous sodium nitrite infusion improves cardiac and pulmonary hemodynamics in heart failure patients. Circ Heart Fail. 2015;8:565–571.
   PubMed Web of Science ®Google Scholar
• Angermann CE, Gelbrich G, Störk S, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail. 2007;9:1212–1222.
   PubMed Web of Science ®Google Scholar
• Ambrosy AP, Butler J, Ahmed A, et al. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014;63:1823–1832.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Teerlink JR, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Eur J Heart Fail. 2015;17:1262–1270.
   PubMed Web of Science ®Google Scholar
• Cotter G, Voors AA, Prescott MF, et al. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail. 2015;17:1133–1143.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29–39.
   PubMed Web of Science ®Google Scholar
• Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and cardiorenal rescue study in acute decompensated heart failure (CARESS-HF). Circ Heart Fail. 2015;8:741–748.
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Januzzi JL. The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. Expert Rev Cardiovasc Ther. 2015;13:1017–1030.
   PubMed Web of Science ®Google Scholar
• Felker GM, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart Fail. 2014;2:457–465.
   PubMed Web of Science ®Google Scholar
• Pitt B, Anker SD, Böhm M, et al. Rationale and design of mineralocorticoid receptor antagonist tolerability study-heart failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224–232.
   PubMed Web of Science ®Google Scholar
• Felker GM, Mentz RJ, Adams KF, et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail. 2015;8:997–1005.
   PubMed Web of Science ®Google Scholar
• Anker SD, Ponikowski P, Mitrovic V, et al. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36:715–723.
   PubMed Web of Science ®Google Scholar
• Felker GM, Butler J, Collins SP, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (biased ligand of the angiotensin receptor study in acute heart failure). JACC Heart Fail. 2015;3:193–201.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378:676–683.
   PubMed Web of Science ®Google Scholar